Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 14 results
Filters: First Letter Of Last Name is V  [Clear All Filters]
Found 14 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

V

Vahey MT, Wang Z, Su Z, et al. "CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway." AIDS Res. Hum. Retroviruses. 2008;24(8):1047-66.
Valcour V, Yeh T-M, Bartt R, et al. "Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection." HIV Med.. 2009;10(2):103-10.
Van Epps P, Matining RM, Tassiopoulos K, et al. "Older age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy." PLoS ONE. 2014;9(9):e107064.
Vandergeeten C, Fromentin R, DaFonseca S, et al. "Interleukin-7 promotes HIV persistence during antiretroviral therapy." Blood. 2013;121(21):4321-9.
Vardhanabhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis CL. "Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230." Open Forum Infect Dis. 2016;3(3):ofw154.
Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJ. "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia." Antivir. Ther. (Lond.). 2015;20(1):73-6.
Vardhanabhuti S, Ribaudo HJ, Landovitz RJ, et al. "Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia." Open Forum Infect Dis. 2015;2(3):ofv085.
Vardhanabhuti S, Acosta EP, Ribaudo HJ, et al. "Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission." J. Infect. Dis.. 2013;208(4):662-71.
Velilla PA, Shata MT, Lages CS, Ying J, Fichtenbaum CJ, Chougnet C. "Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients." AIDS Res. Hum. Retroviruses. 2008;24(1):52-61.
Venuto CS, Mollan K, Ma Q, et al. "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." J. Antimicrob. Chemother.. 2014;69(12):3300-10.
Verma SS, Frase AT, Verma A, et al. "PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG)." Pac Symp Biocomput. 2016;21:57-68.
Vogler MA, Smeaton LM, Wright RL, et al. "Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227." J. Acquir. Immune Defic. Syndr.. 2014;65(5):542-50.
Vogler MA, Patterson K, Kamemoto L, et al. "Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188." J. Acquir. Immune Defic. Syndr.. 2010;55(4):473-82.
Volberding P, Demeter L, Bosch RJ, et al. "Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment." AIDS. 2009;23(15):1987-95.